Spring WARF Therapeutics (WT) Program Proposal Deadline: April 15
If you are a researcher working on a novel biological target, WARF Therapeutics may be able to help advance your work closer to clinical testing. WARF Therapeutics is run by preclinical drug discovery experts who have significant industry experience discovering drugs for novel targets. The program invests in the development of drug-like molecules utilizing industry centric drug discovery resources.
Projects Eligible for WARF Therapeutics
- UW-Madison and Morgridge Institute for Research principle investigators
- Working on translational research with either a validated target and have developed a therapeutic disease hypothesis
- A patent is not required to work with WARF Therapeutics
WARF Therapeutics meets with researchers all year, but the WT board reviews proposals twice a year. The next deadline for submitting a project for board review is April 15 with the review meeting scheduled for May 18. There will be another review in the fall.
If you are interested in learning more about WARF Therapeutics, please contact Jon Young, Head of WARF Therapeutics, at [email protected] or 608.960.9885.
WARF Therapeutics also partners with various departments on campus to sponsor the WARF Therapeutics Drug Discovery seminar series. If your department is interested in participating, please contact Jon Young.
The Wisconsin Alumni Research Foundation (WARF) helps steward the cycle of research, discovery, commercialization and investment for the University of Wisconsin-Madison. Founded in 1925 as an independent, nonprofit foundation, WARF manages more than 2,000 patents and an investment portfolio of $2.7 billion as it funds university research, obtains patents for campus discoveries and licenses inventions to industry. For more information, visit warf.org and view WARF’s Cycle of Innovation.
About WARF Therapeutics
Consistent with WARF’s mission to support UW-Madison research and make a global impact, WARF Therapeutics is a major initiative to move new pharmaceuticals closer to the market and patients. The program will take select assets and lead them through preclinical development, towards commercialization and the benefit of human lives. More at warf.org/therapeutics.